Journal of INDEPENDENT MEDICINE

Creatinine-Guided Furosemide Therapy: A Pathophysiological Framework for Precision Diuretic Use in Critically Ill Patients

Santiago M. Herrero[1]

Abstract

Objective: To propose a physiology-based, creatinine-guided dosing strategy for furosemide administration in critically ill patients with acute decompensated heart failure (ADHF), acute kidney injury (AKI), or chronic kidney disease (CKD), integrating renal function into diuretic decision-making to optimize safety and efficacy.

Data Sources: Relevant literature was identified through searches of PubMed, Embase, and Scopus using the terms *furosemide*, *loop diuretics*, *diuretic resistance*, *organic anion transporters*, *creatinine*, and *renal dysfunction*. Key randomized and mechanistic studies, including the DOSE, Furosemide Stress Test, ADVOR, PUSH-AHF, and ENACT-HF trials, were reviewed.

Data Synthesis: Furosemide efficacy depends on its active tubular secretion via organic anion transporters (OAT1/3). In renal dysfunction, secretion is reduced, uremic toxins compete for transport, and diuretic resistance ensues. Empiric high-dose bolus therapy, common in practice, often leads to suboptimal response or toxicity. A physiologically derived dosing framework is proposed in which the maximum daily dose of furosemide (mg) equals serum creatinine (mg/dL × 88), applicable up to 5 mg/dL. This rule reflects the relationship between creatinine, tubular drug delivery, and the pharmacodynamic threshold for natriuresis.

Conclusions: Serum creatinine serves as a practical surrogate for furosemide delivery to its site of action. The proposed creatinine-guided ceiling rule provides a rational, individualized approach to diuretic therapy that may improve decongestion efficacy while reducing risk of renal and electrolyte complications in critically ill patients.

Keywords: Furosemide, Loop diuretics, Acute decompensated heart failure, Acute kidney injury, Chronic kidney disease, Diuretic resistance, Organic anion transporters, Creatinine-guided dosing, Critical care

Introduction

Congestion is the leading cause of hospital admission in heart failure. Volume overload is also central in advanced CKD and many cases of AKI, where impaired clearance promotes sodium and water retention. The consequences include pulmonary edema, systemic venous hypertension, and impaired organ perfusion. (1)

Loop diuretics are indispensable. Furosemide, in use for over 50 years, is often given empirically in escalating boluses based on crepitations or weight changes, without considering renal function or pharmacokinetics. This practice risks under-dosing, with refractory congestion, or over-dosing, with electrolyte imbalance and toxicity. (2)

There is a need for physiology-based dosing. Serum creatinine, while imperfect, is practical and accessible, and may serve as the basis for structured protocols that improve both safety and efficacy.

Pharmacology of Furosemide

Furosemide blocks NKCC2 in the thick ascending

[1] Policlinico San Donato S.P.A., Iraq Branch, based in Najaf, Iraq

Corresponding author:
Dr. Santiago M. Herrero, MD, FCCP
Chief of Intensive and Critical Care Unit
Policlinico San Donato S.P.A., Iraq Branch, based in Najaf, Iraq
Email: drsantiagoherrero@gmail.com

limb, abolishing the lumen-positive potential and reducing sodium reabsorption. (1) Because >95% of the drug is protein-bound, it is not filtered but must be secreted into the proximal tubule via OAT1 and OAT3. (3) Reduced renal blood flow, competing uremic toxins, or drug interactions limit this secretion and blunt efficacy. (4)

Hypoalbuminemia further reduces delivery, and inflammation modifies transporter activity. Albumin–furosemide co-administration may transiently improve efficiency in hypoalbuminemia, but evidence remains inconsistent. (5)

Creatinine as a Surrogate Marker

Serum creatinine correlates with glomerular filtration rate and, indirectly, with tubular secretory function. (6) In CKD and AKI, impaired clearance leads to accumulation of endogenous organic anions such as indoxyl sulfate and p-cresyl sulfate, which compete with furosemide for OAT1/3 transport. (3) Thus, as creatinine rises, less drug reaches the lumen, shifting the threshold for diuretic response upward. (7)

Creatinine is influenced by muscle mass, diet, and secretion, but remains the most practical bedside marker. (8) In acute illness it is quickly available, reproducible, and already integrated into decision-making for dosing many renally cleared medications. (9) While not perfect, it provides a clinically useful surrogate for predicting diuretic resistance.

Pharmacodynamics of Loop Diuretics

Loop diuretics display a steep, sigmoid dose–response curve. Below a certain threshold concentration in the tubular lumen, there is negligible effect; once exceeded, natriuresis increases rapidly until a ceiling is reached. In renal dysfunction, the curve shifts rightward, meaning that higher plasma doses are needed to achieve effective concentrations. (10)

Continuous infusion offers theoretical advantages by prolonging time above threshold and reducing post-diuretic sodium retention. The DOSE trial compared bolus versus infusion and high versus low dose strategies in ADHF. (11) High-dose therapy improved dyspnea and net fluid loss, though at the expense of transient creatinine elevations, whereas bolus and infusion strategies were broadly similar in efficacy.

Diuretic Resistance

Diuretic resistance refers to a diminished natriuretic or diuretic effect despite administration of sufficiently high doses of loop diuretics. (12) Diuretic resistance arises from multiple interacting mechanisms. Impaired secretion of furosemide through organic anion transporters (OAT1/3) limits drug delivery to its tubular site of action, while chronic loop diuretic exposure induces structural and functional adaptation in the distal nephron—commonly termed the *braking phenomenon*. (2,13) Clinically, this manifests as persistent congestion and poor diuretic response despite progressive dose escalation.

Clinically, resistance manifests as poor urine output despite escalating doses, refractory edema, and recurrent hospitalizations. Observational studies such as PROTECT confirmed that impaired diuretic response strongly predicts worse prognosis in ADHF. (14)

The Creatinine-Guided Ceiling Rule

To translate physiology into practice, a creatinine-based ceiling rule has been proposed:

Maximum daily dose of furosemide (mg) = serum creatinine (mg/dL) × 88, applicable only if creatinine ≤ 5 mg/dL.

This rule acknowledges that as creatinine rises, higher exposure is needed, but also enforces an upper boundary beyond which additional drug is unlikely to achieve benefit and risks toxicity. (15) For instance, a patient with a serum creatinine of 2.0 mg/dL would have a calculated 24-hour maximum of approximately 176 mg (2.0 × 88), which can be rounded to 180 mg — typically administered as 90 mg (half) in an initial bolus followed by 90 mg via continuous infusion or divided intermittent doses (60 mg q8hours). Above creatinine 5 mg/dL, the chance of overcoming resistance is low, and renal replacement therapy should be considered.

This approach introduces discipline to loop diuretic use, avoiding both blind under-dosing and futile escalation (**Table 1**).

Furosemide's pharmacologic efficacy depends on its active secretion via OAT1/3 and delivery to the luminal NKCC2 target. In renal dysfunction, impaired secretion and increased threshold requirements justify a creatinine-guided dosing ceiling that balances efficacy and safety (**Figures 1 and 2**).

Hemodynamic Considerations

Diuretic efficacy depends on renal perfusion. In normotensive or hypertensive patients, venodilators such as intravenous nitroglycerin or nitroprusside reduce filling pressures and rapidly relieve pulmonary congestion while allowing time for laboratory confirmation of creatinine.

In contrast, hypotensive patients require stabilization before loop diuretics. When mean arterial pressure falls below 65 mmHg, vasopressors (norepinephrine) and inotropes (dobutamine or levosimendan) should be initiated to restore renal perfusion. Only after achieving adequate pressure should furosemide be administered within creatinine-guided limits.

Monitoring and Response Assessment

Response to furosemide should be evaluated dynamically. Urine output greater than 100–150 mL/h in the two hours following a diuretic challenge indicates responsiveness, while low output signals resistance. Spot urinary sodium at 2 h is an even better predictor: values >70 mmol/L correlate with effective natriuresis.

Recent pragmatic trials support natriuresis-guided therapy, PUSH-AHF and ENACT-HF showed that early measurement of urinary sodium can guide timely intensification of therapy and improve decongestion. (19) Such strategies integrate seamlessly with a creatinine-based ceiling, ensuring that drug exposure is physiologically adequate without exceeding safe limits.

Safety requires close laboratory monitoring. Electrolytes—especially sodium, potassium, and magnesium—should be checked every 6–12 h. Infusion rates must remain below 4 mg/min (2.5 mg/min in severe renal impairment) to reduce the risk of ototoxicity.

Clinical Trial Evidence

Several trials have shaped modern diuretic strategy (**Table 2**).

These trials collectively demonstrate that loop diuretic therapy should be guided by physiological parameters—renal function, tubular response, and natriuresis—rather than empirical dose escalation alone.

Safety Concerns

Loop diuretics are associated with predictable risks: hypokalemia, hyponatremia, hypomagnesemia, metabolic alkalosis, and volume depletion. (1) Ototoxicity may occur with rapid high-dose boluses, especially in severe renal dysfunction or with concurrent aminoglycosides. (2)

These complications underline the importance of both careful monitoring and adherence to infusion limits.

By anchoring dosing to serum creatinine, the proposed ceiling rule mitigates the tendency to escalate doses beyond physiologic plausibility, thereby reducing the risk of harm.

Future Directions

Further work is needed to validate creatinine-guided dosing in prospective randomized trials. A double-blind RCT comparing the rule with standard empiric care could clarify whether this approach improves decongestion, diuretic efficiency, and safety outcomes.

Integration with natriuresis-guided strategies offers additional promise: creatinine provides the ceiling, while urinary sodium provides the steering. Future protocols may combine both tools in adaptive algorithms.

Finally, advances in transporter biology suggest the possibility of individualized therapy. Genetic variation in OAT transporters, or assays of uremic toxin burden, may one day allow personalized predictions of furosemide response. (21,22)

Conclusion

Furosemide remains essential in the management of fluid overload, but its efficacy is constrained by renal physiology. Serum creatinine provides a practical surrogate for tubular drug delivery and a rational basis for setting dose ceilings. A simple rule—daily dose in milligrams equals creatinine in mg/dL multiplied by 88, applied up to 5 mg/dL—offers a structured, physiologically coherent approach. When integrated with hemodynamic stabilization, sequential nephron blockade, and natriuresis-guided monitoring, creatinine-guided furosemide therapy may transform diuretic use from empiricism to precision.

Key Points

- **Question:** Can serum creatinine serve as a physiologic guide for determining optimal furosemide dosing in patients with heart failure and renal dysfunction?
- **Findings:** Furosemide efficacy depends on active secretion through renal organic anion transporters (OAT1/3), a process impaired in kidney injury. A dosing ceiling proportional to serum creatinine (mg/dL × 88, up to 5 mg/dL) aligns diuretic exposure with renal drug-handling ca-

pacity.

- **Meaning:** A creatinine-guided dosing rule integrates renal function directly into diuretic therapy, potentially preventing both under-dosing and toxicity in critically ill patients.
- **Implication for Practice:** Applying a physiologically informed ceiling for furosemide administration may improve decongestion efficiency and safety compared with conventional empiric dosing strategies.

Funding: No external funding was received for this work.

Conflicts of Interest: The author declares no conflicts of interest related to this manuscript.

Ethical Approval: Not applicable—review article based on published data.

Table 1. Physiological and Clinical Implication

Mechanistic Aspect	Physiological Context	Key Pathophysiology in Renal Dysfunction	Clinical Implication/Relevance	Supporting References
Site of Action (NKCC2 inhibition)	Thick ascending limb of Henle's loop; inhibition of Na^+-K^+-$2Cl^-$ cotransporter (NKCC2) blocks solute reabsorption and disrupts medullary gradient	Reduced delivery of active drug to tubular lumen limits inhibition efficiency	High luminal concentrations are essential for natriuresis; inadequate delivery → diuretic resistance	(1,2)
Protein Binding and Tubular Secretion	>95% plasma protein binding; furosemide secreted via proximal tubular transporters OAT1/3	Reduced renal perfusion, hypoalbuminemia, or OAT competition (by uremic solutes) decreases secretion	Diminished tubular secretion lowers intraluminal concentration and response; justifies higher dosing in renal dysfunction	(1,3–6)
Serum Creatinine as Surrogate Marker	Creatinine reflects GFR and correlates with tubular secretory function	Elevated creatinine signifies reduced OAT-mediated secretion and impaired drug delivery	Provides a pragmatic measure to guide furosemide dosing in the absence of direct transport assessment	(3,6–9)
Dose–Response Curve Characteristics	Sigmoid relationship with steep threshold and defined ceiling	Curve shifts rightward with renal impairment; threshold and ceiling doses increase	Continuous infusion prolongs time above threshold, reducing rebound sodium retention	(10,11)
Braking Phenomenon (Distal Adaptation)	Chronic loop use causes distal nephron hypertrophy and enhanced sodium reabsorption	Persistent congestion despite escalating doses	Sequential nephron blockade (e.g., acetazolamide, thiazide) helps overcome resistance	(2,13)
Hemodynamic Dependence	Effective diuresis requires adequate renal perfusion (MAP ≥ 65 mmHg)	Hypotension or low cardiac output impairs delivery to OAT1/3 sites	Stabilization with vasopressors/inotropes precedes furosemide use in shock states	(10,11)
Creatinine-Guided Dosing Rule	Integrates serum creatinine as a proxy for tubular function	Applies physiologic ceiling: *Maximum daily dose = Creatinine (mg/dL) × 88 (if Cr ≤ 5 mg/dL)*	Prevents excessive dosing beyond tubular capacity; promotes safe, individualized therapy	(15)

Table 2. Clinical Trials Evidence

Trial (Year)	Study Population/Design	Intervention/Comparison	Main Findings	Key Implications
DOSE (2011)Felker et al., *NEJM (11)*	308 patients with acute decompensated heart failure (ADHF)	Bolus vs continuous infusion; high-dose (2.5× home dose) vs low-dose furosemide	High-dose therapy improved symptoms and fluid loss but caused transient rises in creatinine. No major difference between bolus and infusion	Supports aggressive dosing for rapid decongestion with acceptable renal tolerance
Furosemide Stress Test (2013)Chawla et al., *Crit Care (16)*	Patients at risk for or with early AKI	Standardized IV furosemide dose; urine output measured over 2 hours	Urine output response predicted progression of AKI and need for renal replacement therapy (RRT)	Establishes furosemide response as a dynamic marker of tubular function and prognosis
ADVOR (2022)Mullens et al., *NEJM (17)*	519 patients with ADHF and volume overload	Acetazolamide + loop diuretic vs loop diuretic alone	Combination therapy accelerated decongestion and improved diuretic efficiency	Highlights benefit of sequential nephron blockade to enhance loop diuretic response
PUSH-AHF (2023)Schouten et al., *Nat Med (18)*	Hospitalized patients with ADHF	Natriuresis-guided diuretic adjustment vs standard care	Natriuresis-guided dosing improved efficiency and early decongestion	Demonstrates feasibility and benefit of natriuresis-based titration
ENACT-HF (2022–24)ter Maaten et al., *Eur J Heart Fail*; Dauw et al., *Circ Heart Fail (20)*	Multicenter, randomized pragmatic trial in ADHF	Standardized natriuresis-guided algorithm vs clinician-directed diuretic therapy	Improved 24-hour natriuresis and decongestion efficiency without excess renal adverse events	Confirms clinical value of integrating natriuresis monitoring into diuretic protocols

Figure 1. Creatinine-Guided Furosemide Mechanism and Dosing Framework



Figure 2. Stepwise Algorithm



The calculated dose can be administered as an initial half intravenous bolus followed either by continuous infusion or by intermittent doses every 8 to 12 hours, depending on hemodynamic stability and urine output response.

References

1. Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377:1964–75. doi:10.1056/NEJMra1703100.
2. Wilcox CS, Testani JM, Pitt B. Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. Hypertension. 2020 Oct;76(4):1045–1054. doi: 10.1161/HYPERTENSIONAHA.120.15205.
3. Wu W, Bush KT, Nigam SK. Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes. Sci Rep. 2017 Jul 10;7(1):4939. doi: 10.1038/s41598-017-04949-2.
4. Benzi, J. R. d. L., Melli, P. P. d. S., Duarte, G., Unadkat, J. D., & Lanchote, V. L. (2023). The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis. Pharmaceutics, 15(10), 2427. doi:10.3390/pharmaceutics15102427
5. Lee TH, et al. Co-administration of furosemide + albumin vs furosemide alone: updated meta-analysis. PLoS One. 2021;16:e0260312. doi:10.1371/journal.pone.0260312.
6. Wang X, Mu J, Ma K, Ma Y. Challenges of Serum Creatinine Level in GFR Assessment and Drug Dosing Decisions in Kidney Injury. Adv Pharm Bull. 2024 Dec 30;14(4):745–758. doi: 10.34172/apb.42345
7. Ferrari F, Zanza C, Tesauro M, Longhitano Y, Planinsic R, Voza A, Fumagalli J, Scaravilli V, Grasselli G. Clinical Pharmacology of Loop Diuretics in Critical Care. Clin Pharmacokinet. 2025 Jul;64(7):987–997. doi: 10.1007/s40262-025-01524-1.
8. Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar-Zadeh K. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013 Mar;4(1):19–29. doi: 10.1007/s13539-012-0079-1.
9. Damman, K., Valente, M.A., Voors, A.A., O'Connor, C.M., van Veldhuisen, D.J. & Hillege, H.L Renal impairment, worsening renal function, and outcome in heart failure: updated meta-analysis. Eur Heart J. 2014;35:455–69. doi:10.1093/eurheartj/eht386.
10. Oh SW, Han SY. Loop Diuretics in Clinical Practice. Electrolyte Blood Press. 2015 Jun;13(1):17–21. doi: 10.5049/EBP.2015.13.1.17.
11. Felker GM, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE). N Engl J Med. 2011;364:797–805. doi:10.1056/NEJMoa1005419.
12. Marques P, Blydt-Hansen M, Takano T, Ferreira JP, Tsoukas MA, Sharma A, Mavrakanas TA. Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease. Cardiorenal Med. 2025;15(1):462–483. doi: 10.1159/000546520.
13. Casu G, Merella P. Diuretic Therapy in Heart Failure - Current Approaches. Eur Cardiol. 2015 Jul;10(1):42–47. doi: 10.15420/ecr.2015.10.01.42.
14. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014 May 14;35(19):1284–93. doi: 10.1093/eurheartj/ehu065.
15. Herrero S. Varon J. Manejo de la insuficiencia cardíaca aguda descompensada. JANO: Medicina y Humanidades. 2008;1681:33–43 ISSN: 0210-220X. Elsevier Doyma. (Spanish Language). http://bit.ly/3L0tzBU
16. Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013 Sep 20;17(5):R207. doi: 10.1186/cc13015.
17. Mullens, W., Dauw, J., Martens, P., Verbrugge, F.H., Nijst, P., Meekers, E., et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR). N Engl J Med. 2022;387:1185–95. doi:10.1056/NEJMoa2203094.
18. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Coster JE, Nieuwland W, van Veldhuisen DJ, Voors AA, Damman K. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022 Feb;24(2):385–392. doi: 10.1002/ejhf.2385.
19. Ter Maaten, J.M., Beldhuis, I.E., van der Meer, P. *et al.* Natriuresis-guided diuretic therapy in

acute heart failure: a pragmatic randomized trial. *Nat Med* 29, 2625–2632 (2023). https://doi.org/10.1038/s41591-023-02532-z
20. Dauw J, Charaya K, Lelonek M, Zegri-Reiriz I, Nasr S, Paredes-Paucar CP, et al. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study. Circ Heart Fail. 2024 Jan;17(1): e011105. doi: 10.1161/CIRCHEARTFAILURE.123.011105.
21. Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic Anion Transporters & implications in pharmacotherapy. Pharmacol Rev. 2012;64:421–449. doi:10.1124/pr.110.003531.
22. Xu C, Wang J. Regulation of renal OATs: physiology & pathophysiology. Pharmacol Ther. 2021;223:107806. doi:10.1016/j.pharmthera.2020.107806.